Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: The Losartan Intervention for Endpoint reduction in hypertension study

Blood Pressure

Volumn 18, Issue 6, 2009, Pages 348-361

  Kjeldsen, Sverre E ^a,e   Devereux, Richard B ^b   Hille, Darcy A ^c   Lyle, Paulette A ^c   Dahlf, Bjrn ^d   Julius, Stevo ^e   Edelman, Jonathan M ^c   Snapinn, Steven M ^c   De Faire, Ulf ^f   Fyhrquist, Frej ^g   Ibsen, Hans ^h   Lederballe Pedersen, Ole ⁱ   Lindholm, Lars H ^j   Nieminen, Markku S ^g   Omvik, Per ^k   Oparil, Suzanne ^l   Wedel, Hans ^m  

^a UNIVERSITY OF OSLO   (Norway)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h HOLBÆK HOSPITAL   (Denmark)

ⁱ VIBORG HOSPITAL   (Denmark)

^j UMEÅ UNIVERSITY   (Sweden)

^k HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

more..

Author keywords

Cardiovascular disease; Hypertension; Left ventricular hypertrophy; Risk factors

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; ATENOLOL; CREATININE; GLUCOSE; HYDROCHLOROTHIAZIDE; LOSARTAN;

ADULT; AGE DISTRIBUTION; AGED; ALBUMINURIA; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DEATH; DIABETES MELLITUS; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULSE PRESSURE; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE; SMOKING HABIT; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED;

EID: 73649104443     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037050903460590     Document Type: Article

References (28)

1. Dahlof B, Devereux R, De Faire U, Fyhrquist F, Hedner T, Ibsen H, et al.. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: Rationale, design, and methods. The LIFE Study Group. Am J Hypertens. 1997; 10:705-713.
2. Dahlof B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, De Faire U, et al.. Characteristics of 9194 patients with left ventricular hypertrophy: The LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension. 1998;32:989-997.
3. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, et al.. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995-1003.
4. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, De Faire U, et al.. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:1004-1010.
5. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profi le. A statement for health professionals. Circulation. 1991;83:356-362.
6. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
7. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
8. Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA. 1995;273:1592-1597.
9. Otterstad JE, Smiseth O, Kjeldsen SE. Hypertensive left ventricular hypertrophy: Pathophysiology, assessment and treatment. Blood Press. 1996;5:5-15.
10. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: A risk profi le from the Framingham Study. Stroke. 1991;22:312-318.
11. Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ. 2001;323:75-81.
12. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285.
13. Sandvik L, Erikssen J, Ellestad M, Erikssen G, Thaulow E, Mundal R, et al.. Heart rate increase and maximal heart rate during exercise as predictors of cardiovascular mortality: A 16-year follow-up study of 1960 healthy men. Coron Artery Dis. 1995;6:667-679.
14. De Simone G, Wachtell K, Palmieri V, Hille DA, Beevers G, Dahlof B, et al.. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: The LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. Circulation. 2005;111:1924-1931.
15. Gueyffier F, Boissel JP, Pocock S, Boutitie F, Coope J, Cutler J,et al.. Identifi cation of risk factors in hypertensive patients: Contribution of randomized controlled trials through an individual patient database. Circulation. 1999;100:e88-e94.
16. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al.. General cardiovascular risk profi le for use in primary care. The Framingham Heart Study. Circulation. 2008;117;743-753.
17. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al.. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J. 2003;24:987-1003.
18. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: Prospective open cohort study. BMJ. 2007;335:136.
19. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds risk score. JAMA. 2007;297:611-619.
20. Woodward M, Brindle P, Tunstall-Pedoe H, for the SIGN Group on Risk Evaluation. Adding social deprivation and family history to cardiovascular risk assessment: The ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007;93:172-176.
21. Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol. 2007;2:581-590
22. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al.. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study. Ann Intern Med. 2003;139:901-906.
23. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al.. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in patients with hypertension and left ventricular hypertrophy? A LIFE substudy. J Hypertens. 2004; 22:1805-1811.
24. Lee ET, Howard BV, Wang W, Welty TK, Galloway JM, Best LG, et al.. Prediction of coronary heart disease in a population with high prevalences of diabetes and albuminuria: The Strong Heart Study. Circulation. 2006;113:2897-2905.
25. Dahlof B, Burke TA, Krobot K, Carides GW, Edelman JM, Devereux RB, et al.. Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Hum Hypertens. 2004;18:367-373.
26. Mahoney, DW, Atkinson, EJ. Technical Report Series: Receiver operating characteristic (ROC) curves using S-Plus. Rochester, MN: Department of Health Science Research, Mayo Clinic; 2004.
27. Lemeshow S, Hosmer DW Jr. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol. 1982;115:92-106.
28. D'Agostino R, Nam BH. Evaluation of the performance of survival analysis models: Discrimination and calibration measures. In: Handbook of statistics. Amsterdam: Elsevier; 2004. p 1-25.